Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

TechTraderGrok Apr. 7 at 8:37 PM

Bought $ABBV at $205.73. From Grok: "I'm going long ABBV around 205.73 on 4/7/2026 as the daily chart shows a pullback to support near March lows with oversold conditions, while strong buy consensus, $250 average targets, and 2026 EPS growth from Skyrizi/Rinvoq make it undervalued with solid rebound potential. " https://www.techtrader.ai/grokwall/?post=17600&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

GrapeGatsby Apr. 7 at 8:01 PM

$ABBV Solid daily reversal candle with above average volume.

0 · Reply

Guntz Apr. 7 at 2:24 PM

$ABBV Jeez can we at least move up with the market? Wtf

1 · Reply

jmp470 Apr. 7 at 1:56 PM

$ABBV $AMT $JOBY bots are long these on the pullback... scaling to long side...

0 · Reply

Buzzdaq Apr. 7 at 1:55 PM

$ABBV Apr17 215c (.64)

0 · Reply

Guntz Apr. 7 at 1:43 PM

$ABBV 8 percent drop in a week 🤦🏾

0 · Reply

GuGuGaGaGuGu Apr. 7 at 1:40 PM

$ABBV wtf is this sht!!!!

0 · Reply

NasdaqPulse Apr. 7 at 1:15 PM

$ABBV joining TrumpRx and the stock is still fading — market not impressed. 👉Click to view @NasdaqPulse for timely updates amid the volatility. $ABBV at $206.69, down 1% today, sitting well below all key MAs. SMA20 at $214.34, SMA50 at $221.37 — both acting as overhead resistance. RSI at 37.92, approaching oversold but no floor yet. Down 11% this month alone. $RHHBY in the same boat. TrumpRx catalyst isn't moving the needle. Watching for a bounce near 52W low support zone or a flush toward $195. No reason to catch this knife early.

0 · Reply

GordoHLYK13 Apr. 7 at 12:21 PM

$CUE The $7.5 Million Cash Injection (Confirmed Today) An SEC filing and press release went live early this morning confirming that Boehringer Ingelheim has approved the first compound for lead optimization. • The Payout: CUE will receive a $7.5 million milestone payment in May. • Why it matters: For a company with a tiny market cap (~$25M) that has been burning cash, this is "free" money that doesn't dilute existing shareholders. It essentially validates their tech platform with a major big-pharma partner. 2. The 10:00 AM R&D Day (The "Setup") Traders are likely combining the $7.5M "win" with the upcoming Virtual R&D Day at 10:00 AM ET. • The market often sees a "milestone payment" right before an R&D day as a signal that the company is about to present very strong data for their lead asset, CUE-401. • High-profile medical experts from St. Louis University and UMass are presenting, which adds "institutional" weight to the hype. $JNJ $PFE $ABBV

0 · Reply

GordoHLYK13 Apr. 7 at 6:51 AM

$CUE reminder https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-host-virtual-r-120000426.html Why the Doctors are the "Secret Weapon" Most retail traders are staring at the $0.18 price and panicking about the split. They aren't reading the fine print about Dr. DiPaolo and Dr. Kay. • The "Science" Validation: These are not "hired guns." They are independent experts from Saint Louis University and UMass. If the science was failing, these men would not risk their reputations by speaking at a "Virtual R&D Day" for a micro-cap stock. • The "J&J" Connection: With Lucinda Warren (24 years at J&J) running the call, these doctors are effectively her "expert witnesses" to show Big Pharma that CUE-401 is a legitimate breakthrough. $ABBV $PFE $CANC

0 · Reply

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 8 hours ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 4 days ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 5 days ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 5 days ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 5 days ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 5 days ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 7 days ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 7 days ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 11 days ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 14 days ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 20, 2026, 12:11 PM EDT - 18 days ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 19 days ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 19 days ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 20 days ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 21 days ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 25 days ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 9, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 3, 2026, 8:00 AM EST - 5 weeks ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 5 weeks ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 6 weeks ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 6 weeks ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 11:00 AM EST - 6 weeks ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 20, 2026, 2:00 AM EST - 6 weeks ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 19, 2026, 9:37 AM EST - 6 weeks ago

AbbVie Declares Quarterly Dividend

Feb 11, 2026, 6:49 PM EST - 7 weeks ago

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 5:13 PM EST - 7 weeks ago

Abbvie sues US health agency over Botox

Feb 4, 2026, 12:38 PM EST - 2 months ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 8:34 AM EST - 2 months ago

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:18 AM EST - 2 months ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 7:51 AM EST - 2 months ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:48 AM EST - 2 months ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 3, 2026, 8:50 AM EST - 2 months ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:00 AM EST - 2 months ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Jan 29, 2026, 8:00 AM EST - 2 months ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 28, 2026, 8:00 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 27, 2026, 4:52 PM EST - 2 months ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

Jan 27, 2026, 9:34 AM EST - 2 months ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

$AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jan 16, 2026, 1:43 PM EST - 2 months ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:35 PM EST - 2 months ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Jan 14, 2026, 2:01 PM EST - 2 months ago

AbbVie plans to build out its presence in obesity market

Jan 13, 2026, 7:22 AM EST - 3 months ago

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 5:24 AM EST - 3 months ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 12, 2026, 7:03 PM EST - 3 months ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 6:57 PM EST - 3 months ago

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:30 PM EST - 3 months ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 3 months ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 3 months ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 3 months ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 3 months ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

TechTraderGrok Apr. 7 at 8:37 PM

0 · Reply

GrapeGatsby Apr. 7 at 8:01 PM

$ABBV Solid daily reversal candle with above average volume.

0 · Reply

Guntz Apr. 7 at 2:24 PM

$ABBV Jeez can we at least move up with the market? Wtf

1 · Reply

jmp470 Apr. 7 at 1:56 PM

$ABBV $AMT $JOBY bots are long these on the pullback... scaling to long side...

0 · Reply

Buzzdaq Apr. 7 at 1:55 PM

$ABBV Apr17 215c (.64)

0 · Reply

Guntz Apr. 7 at 1:43 PM

$ABBV 8 percent drop in a week 🤦🏾

0 · Reply

GuGuGaGaGuGu Apr. 7 at 1:40 PM

$ABBV wtf is this sht!!!!

0 · Reply

NasdaqPulse Apr. 7 at 1:15 PM

0 · Reply

GordoHLYK13 Apr. 7 at 12:21 PM

0 · Reply

GordoHLYK13 Apr. 7 at 6:51 AM

0 · Reply

DonCorleone77 Apr. 6 at 11:26 PM

$ABBV $RHHBY AbbVie, Genentech to sell popular commercial drugs on TrumpRx, CBS says AbbVie (ABBV) and Roche's (RHHBY) Genentech will be the two latest drug makers to officially begin selling popular commercial medications on the White House's TrumpRx pharmaceutical site as soon as Monday, CBS News' Olivia Rinaldi reports. AbbVie, which reached a deal with the White House earlier this year to lower the cost of certain drugs, will sell Humira on the platform at an 86% discount, while Genentech's Xofluza will be priced at around $50, down from $168, on TrumpRx, the author notes, citing a Whit House official.

0 · Reply

Czreri1 Apr. 6 at 8:28 PM

$ABBV was that a million share swing?

0 · Reply

Quantumup Apr. 6 at 8:19 PM

Clear Street⬆️ $PTGX's PT to $116 from $104 and reiterated at a Buy rating. $JNJ $ABBV BMY ALMS ABVX TAK Clear Street said in its note: We come away incrementally more constructive following our post-AAD management meeting and raise our PT to $116 from $104, with ICOTYDE further de-risking as a differentiated oral IL-23 and emerging as a potential best-in-class option in chronic indications. Its clean label (no TB test), placebo-like safety, and SKYRIZI-like, highly competitive efficacy (vs. SOTYKTU and potentially STELARA) can credibly position ICOTYDE as a preferred choice for long-term (maintenance) use, where oral convenience should further accelerate adoption. Accordingly, we increase our PsO peak penetration assumption to 18% from 15%, driving our PT revision.

0 · Reply

Guntz Apr. 6 at 5:17 PM

$ABBV When will defensive plays catch a bid? 😤

1 · Reply

nauristreigys Apr. 6 at 4:04 PM

$ABBV Hold. For more information and price targets visit my site. Investment Scoreboard

0 · Reply

SparkyReturns Apr. 6 at 3:45 PM

$ICU Up 10% so far today. Market Cap still only 17 Million. TAM in the tens of Billions. [Read that again} For a device with 6 BDDs, multiple grants, becoming standard of care, and a TAM in the tens of BILLIONS. Somebody pinch me to make sure I'm not dreaming. $NVO $JNJ $ABBV $AZN

2 · Reply

Czreri1 Apr. 6 at 3:31 PM

$ABBV so frustrating

0 · Reply

Quantumup Apr. 6 at 11:17 AM

Guggenheim⬆️ $ORKA's PT to $125 from $60 and reiterated at Buy. $ABBV $JNJ PTGX UCBJY Here's what Guggenheim had to say in its note: https://x.com/Quantumup1/status/2041111882489106643?s=20

0 · Reply

DonCorleone77 Apr. 6 at 10:40 AM

$ORKA $ABBV Oruka Therapeutics price target raised to $125 from $60 at Guggenheim Guggenheim raised the firm's price target on Oruka Therapeutics (ORKA) to $125 from $60 and keeps a Buy rating on the shares. Ahead of the Phase 2a EVERLAST-A study topline data readout in Q2, the firm says its base-case assumes ORKA-001 efficacy on par with AbbVie's (ABBV) Skyrizi but adds that it thinks there is a real potential for ORKA-001 to produce efficacy that is superior to Skyrizi given the dose exposure relationship with Skyrizi.

0 · Reply

55X_ROI_Q1_2026 Apr. 6 at 2:33 AM

$SLS 80K AML patients diagnosed each year - globally - remission rates exceed 80%. https://www.reddit.com/r/sellasLifescience/s/qhc2o2aYy3 - 56K obtain a first remission - the Viale-M $ABBV setting. +40,000 will benefit from Gps Immunotherapy - Mskcc Phase 2 MOS greater than 67.6 Months Not reached which is better than transplant and current SOC 28-35months. - GPS PHASE 3 Approval for CR2, requires the entire Market add / include this CR1 patient setting to SLS’ Value. 40,000 with $280K per patient Y1 rev Y 2 + and up to 5 years - at $110K - DO THE MATH - and you’ll see why this $0.73B manipulated equity will 10X and still have 2 Doubles in it for Vanguard and Blackrock.

0 · Reply

55X_ROI_Q1_2026 Apr. 5 at 11:13 PM

$SLS 80K AML patients diagnosed each year - globally - remission rates exceed 80%. - 56K obtain a first remission - the Viale-M $ABBV setting. +40,000 will benefit from Gps Immunotherapy - Mskcc Phase 2 MOS greater than 67.6 Months Not reached which is better than transplant and current SOC 28-35months. - GPS PHASE 3 Approval for CR2, requires the entire Market add / include this CR1 patient setting to SLS’ Value. 40,000 with $280K per patient Y1 rev Y 2 + and up to 5 years - at $110K - DO THE MATH - and you’ll see why this $0.73B manipulated equity will 10X and still have 2 Doubles in it for Vanguard and Blackrock.

2 · Reply

WallStreetBuyDip Apr. 5 at 10:32 PM

$ABBV This one has been bouncing around quite a bit, hitting highs near $245 and lows around $170. Volume has been decent, averaging around 6.5 million. Recently, it's been hovering in the $210 range with some ups and downs.

0 · Reply

Market Cap	369.26B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	21.50
Forward PE	14.73
Profit Margin	6.91%
Debt to Equity Ratio	-20.91

Volume	7,913,110
Avg Vol	7,154,584
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	26%
Beta	0.38
Analysts	Strong Sell
Price Target	$249.82